The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions.
Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group. Safety: All adverse events are summarized in terms of the number of subjects, expression rate, and number of expressions of adverse reactions by treatment group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
47
* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101 * Administration orally with 150 mL of water under fasting conditions
* Administration alone of 1 tablet of JW0107 * Administration orally with 150 mL of water under fasting conditions
Clinical Trial Center, Jeonbuk National University Hospital
Jeonju, Korea, South Korea
AUCt
Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Time frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Cmax
Describes the blood concentration statistically by pharmacokinetic blood
Time frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.